Besides, more patients had actionable variants of level 3 than level 4 (39.53% vs 4.65%), as nearly a quarter of the cervical cancer patients had actionable of alterations in PIK3CA, which may confer sensitivity to the PI3K or mTOR inhibitors. This evidence concerns the gene MTOR and cervical carcinoma.